Lady at 37130 viejo

Added: Kathlene Michael - Date: 18.11.2021 14:49 - Views: 24108 - Clicks: 4830

Study record managers: refer to the Data Element Definitions if submitting registration or information.

Lady at 37130 viejo

Talk with your doctor and family members or friends about deciding to a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or information. Search for terms. Save this study.

Lady at 37130 viejo

Warning You have reached the maximum of saved studies A Study of Ibandronate Boniva to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.

Federal Government. Read our disclaimer for details. Last Update Posted : November 2, Study Description. This study will investigate participant satisfaction including compliance, preference, tolerability with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is individuals.

Drug Information available for: Ibandronic acid Ibandronate sodium. FDA Resources. Arms and Interventions. Film-coated oral ibandronate tablet mg once-monthly. Outcome Measures. Primary Outcome Measures : Part A: of participants who currently use weekly biphosphonate who answer "yes" to any of the questions in Candidate Identification Questionnaire CIQ [ Time Frame: Up to 30 days prior to baseline visit ] Part B: of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate [ Time Frame: 6 months ] Part B: Percentage of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate [ Time Frame: 6 months ].

Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Lady at 37130 viejo. Information from the Lady at 37130 viejo Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information.

Lady at 37130 viejo

National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety Lady at 37130 viejo scientific validity of this study is the responsibility of the study sponsor and investigators. Postmenopausal Osteoporosis. Drug: Ibandronate. Phase 4. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Experimental: Ibandronate Participants will receive milligrams mg of ibandronate as a film-coated tablet once-monthly.

Westlake Village, California, United States, Colorado Springs, Colorado, United States, Fayetteville, North Carolina, United States, Wilmington, North Carolina, United States, Winston-salem, North Carolina, United States, Philadelphia, Pennsylvania, United States, Charleston, South Carolina, United States, Spartanburg, South Carolina, United States, November 13, Key Record Dates.

Lady at 37130 viejo Lady at 37130 viejo

email: [email protected] - phone:(483) 629-7101 x 4836

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia